Last reviewed · How we verify
PF06263276
At a glance
| Generic name | PF06263276 |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis (PHASE1)
- A Phase 1 Study To Evaluate Tolerability, Safety, And Pharmacokinetics Of Topical PF-06263276 In Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF06263276 CI brief — competitive landscape report
- PF06263276 updates RSS · CI watch RSS
- Pfizer portfolio CI